SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?

Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo, NN8022-1922 Study Group, Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial JAMA. ,vol. 314, pp. 687- 699 ,(2015) , 10.1001/JAMA.2015.9676

Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal, Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes Diabetes Care. ,vol. 38, pp. 2009- 2017 ,(2015) , 10.2337/DC15-0779

Hadi Harati, Vandhna Sharma, Abbas Motazedi, Sodium‐glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes Journal of Diabetes. ,vol. 8, pp. 165- 165 ,(2016) , 10.1111/1753-0407.12330

Jamie C. Diner, Irl B. Hirsch, Anne L. Peters, Elizabeth O. Buschur, John B. Buse, Pejman Cohan, Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition Diabetes Care. ,vol. 38, pp. 1687- 1693 ,(2015) , 10.2337/DC15-0843

Andrew Anglemyer, Hacsi T Horvath, Lisa Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials Cochrane Database of Systematic Reviews. ,(2014) , 10.1002/14651858.MR000034.PUB2

P. Sedgwick, Bias in observational study designs: prospective cohort studies BMJ. ,vol. 349, ,(2014) , 10.1136/BMJ.G7731

Paul Nyirjesy, Jack D. Sobel, Albert Fung, Cristiana Mayer, George Capuano, Kirk Ways, Keith Usiskin, Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies Current Medical Research and Opinion. ,vol. 30, pp. 1109- 1119 ,(2014) , 10.1185/03007995.2014.890925

Simeon I Taylor, Jenny E Blau, Kristina I Rother, Possible adverse effects of SGLT2 inhibitors on bone. The Lancet Diabetes & Endocrinology. ,vol. 3, pp. 8- 10 ,(2015) , 10.1016/S2213-8587(14)70227-X

Lars Hansen, Nayyar Iqbal, Ella Ekholm, William Cook, Boaz Hirshberg, Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocrine Practice. ,vol. 20, pp. 1187- 1197 ,(2014) , 10.4158/EP14489.OR

Tobias Gerhard, Bias: Considerations for research practice American Journal of Health-system Pharmacy. ,vol. 65, pp. 2159- 2168 ,(2008) , 10.2146/AJHP070369